Healthcare / BiotechnologyShanghai
$3.55
-0.01 (-0.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $38.1M · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-35.3%
↓Gross Margin
72.2%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-14.4%
FCF CAGR
-44.5%
FCF margin
24.8%
FCF / Net income
-0.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $187.9M · net income $-311.4M · FCF $46.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $187.9M | $187.9M | $271.0M | $240.7M | $300.0M |
| Net Income | $-311.4M | $-311.4M | $171.2M | $62.9M | $121.6M |
| EBITDA | $-165.7M | $-165.7M | $251.0M | $101.1M | $188.9M |
| EPS | -0.48 | -0.48 | 0.26 | 0.10 | 0.19 |
| Gross Margin | 72.2% | 72.2% | 60.2% | 51.4% | 59.0% |
| Operating Margin | 25.1% | 25.1% | 10.9% | 2.1% | 22.2% |
| Net Margin | -165.8% | -165.8% | 63.2% | 26.1% | 40.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.01 | 0.04 | 0.04 |
| Current Ratio | 4.27 | 4.27 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $46.7M | $46.7M | $38.1M | $-16.2M | $273.1M |
| Returns | |||||
| ROE | -35.3% | -35.3% | 11.0% | 5.2% | 10.7% |
| Valuation | |||||
| P/E | — | — | 24.85 | 101.50 | 52.21 |
| EV/EBITDA | — | — | 15.58 | 62.22 | 33.00 |
| P/B | 2.67 | 2.67 | 2.73 | 5.24 | 5.57 |
| Growth & Yield | |||||
| Revenue Growth | -30.7% | -30.7% | 12.6% | -19.8% | — |
| EPS Growth | -284.6% | -284.6% | 160.0% | -47.4% | — |
| Dividend Yield | 2.2% | 2.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-46.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.26 → -0.48
Residual
-49.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.